Jointown subsidiary's restructuring investment in Aoyuan Meigu approved by court

Jointown Pharmaceutical Group announced that its wholly-owned subsidiary, Hubei Jiuzhou Industrial Park Operation and Management Co., Ltd. (Jiuzhou Property Investment Company), has secured court approval for its restructuring investment in Aoyuan Meigu Technology Co., Ltd. The Xiangyang Intermediate People's Court approved the restructuring plan and terminated Aoyuan Meigu's restructuring procedures on December 16, 2025. This decision follows an initial investment agreement on April 23, 2025, to acquire 360,000,000 shares for 673,200,000.00 yuan, later adjusted on September 24, 2025, to 435,930,312 shares for 706,207,105.44 yuan.

The company anticipates this investment aligns with its long-term strategic growth, enhancing its core competitiveness through supply chain integration and product development in the beautiful health industry. Despite the approval, Jointown highlights potential uncertainties regarding the full implementation and expected returns, advising investors to exercise caution.

In related news, Jointown's controlling shareholder, Chuchang Investment Group Co., Ltd., completed the repayment and delisting of its 2022 non-publicly issued exchangeable corporate bonds (second tranche) on December 16, 2025. This move frees up 23,841,539 shares of Jointown Pharmaceutical Group stock previously held as collateral and trust property, which will be transferred back to Chuchang Investment's securities account.